Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs).

被引：0
|
作者：
Sibon, David [1 ]
Cannas, Giovanna [2 ]
Barraco, Fiorenza [2 ]
Prebet, Thomas [3 ]
Vey, Norbert [4 ]
Banos, Anne [5 ]
Besson, Caroline [6 ]
Corm, Selim [7 ]
Blanc, Michel [7 ]
Slama, Borhane [8 ]
Perrier, Herve [2 ]
Fenaux, Pierre [9 ]
Wattel, Eric [2 ]
机构：
[1] GFM, Paris, France
[2] GFM, Lyon, France
[3] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France
[4] Hop Paoli Calmettes, Marseille, France
[5] GFM, Bayonne, France
[6] Univ Paris 11, CHU Bicetre, INSERM, U1012, Le Kremlin Bicetre, France
[7] GFM, Chambery, France
[8] GFM, Avignon, France
[9] Univ Paris 13, Hop Avicenne, Serv Hematol Clin, Bobigny, France
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1632 / 1632
页数：1
相关论文
共 50 条
  • [31] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    Giagounidis, Aristoteles
    List, Alan F.
    Selleslag, Dominik
    Mittelman, Moshe
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Li, Jack Shiansong
    Sugrue, Mary M.
    Fenaux, Pierre
    BLOOD CANCER JOURNAL, 2018, 8
  • [32] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Mikkael A. Sekeres
    Arlene S. Swern
    Aristoteles Giagounidis
    Alan F. List
    Dominik Selleslag
    Moshe Mittelman
    Brigitte Schlegelberger
    Gudrun Göhring
    Jack Shiansong Li
    Mary M. Sugrue
    Pierre Fenaux
    Blood Cancer Journal, 8
  • [33] Prognosis of Lower Risk Patients with Myelodysplastic Syndromes without Isolated Del(5q) after Failure of Erythropoiesis-Stimulating Agents. a Multicenter Study By the Hellenic MDS Study Group
    Galanopoulos, Athanasios G.
    Kontos, Christos K.
    Symeonidis, Argiris
    Kotsianidis, Ioannis
    Kourakli, Alexandra
    Pappa, Vassiliki
    Tsiambalis, Thomas
    Pouli, Anastasia
    Panayiotidis, Panayiotis
    Roussou, Paraskevi
    Karakatsanis, Stamatis
    Zafeiropoulou, Kalliopi
    Dimou, Maria
    Vassilakopoulos, Theodoros P.
    Vardi, Anna
    Tsokanas, Dimitrios
    Drakos, George
    Hatzimichael, Eleftheria
    Megalakaki, Aikaterini
    Repousis, Panagiotis
    Kotsopoulou, Maria
    Solomou, Elena E.
    Kaiafa, Georgia
    Papoutselis, Menelaos Konstantinos
    Sioni, Anastasia
    Charchalakis, Nikolaos
    Bouronikou, Eleni
    Vassilopoulos, George
    Lazaris, Vasileios
    Galanopoulos, Athanasios
    Diamantopoulos, Panagiotis Theodorou
    Kontopidou, Flora
    Topouzoglou, Zoi
    Kalyva, Stamatina
    Papadaki, Helen A.
    Hatzitolios, Apostolos
    Anagnostopoulos, Achilles
    Anagnostopoulos, Nikolaos
    Viniou, Nora-Athina
    BLOOD, 2017, 130
  • [34] Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)
    Almeida, Antonio
    Fenaux, Pierre
    List, Alan F.
    Raza, Azra
    Platzbecker, Uwe
    Santini, Valeria
    LEUKEMIA RESEARCH, 2017, 52 : 50 - 57
  • [35] Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes: Systematic Literature Review
    Boccia, Ralph, V
    Deshpande, Sohan
    Von Wilamowitz-Moellendorff, Caroline
    Raorane, Renuka
    Klijn, Sven L.
    Xiao, Hong
    Yucel, Aylin
    BLOOD, 2022, 140 : 12355 - 12356
  • [36] Lower-Risk Myelodysplastic Syndromes: Erythropoiesis-Stimulating Agent Treatment Approaches and Outcomes in the United States
    Savill, Kristin M. Zimmerman
    Gajra, Ajeet
    Price, Kwanza
    Kish, Jonathan K.
    Brown-Bickerstaff, Cherrishe
    Falkenstein, Angelica
    Miller, Talia
    Laney, JaLyna
    Mukherjee, Sudipto
    BLOOD, 2021, 138
  • [37] A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes
    Boccia, Ralph
    Xiao, Hong
    von Wilamowitz-Moellendorff, Caroline
    Raorane, Renuka
    Deshpande, Sohan
    Klijn, Sven L.
    Yucel, Aylin
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (09)
  • [38] Early Treatment of Anemia of Lower Risk MDS by Erythropoiesis-Stimulating Agents (ESAs): A Report On 112 Cases
    Park, Sophie
    Kelaidi, C.
    Sapena, Rosa
    Vassilieff, D.
    Beyne-Rauzy, Odile
    Coiteux, Valerie
    Vey, Norbert
    Ravoet, Christophe
    Cheze, Stephane
    Rose, Christian
    Legros, Laurence
    Stamatoullas, Aspasia
    Escoffre-Barbe, Martine
    Guerci, Agnes
    Chaury, M. P.
    Fenaux, Pierre
    Dreyfus, Francois
    BLOOD, 2009, 114 (22) : 701 - 702
  • [39] Continuous Transfusion Independence With Imetelstat in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Neoplasms Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase III
    Platzbecker, Uwe
    Santini, Valeria
    Fenaux, Pierre
    Sekeres, Mikkael
    Savona, Michael
    Madanat, Yazan
    Diez-Campelo, Maria
    Valcarcel-Ferreiras, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Xia, Qi
    Peng, Lixian
    Sun, Libo
    Wang, Ying
    Huang, Fei
    Ikin, Annat
    Navada, Shyamala
    Feller, Faye
    Komrokji, Rami
    Zeidan, Amer
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S371 - S371
  • [40] High Cereblon Expression In Lower Risk Myelodysplastic Syndromes With 5q Deletion Is Associated With The Efficacy Of Lenalidomide
    Jonasova, Anna T.
    Polak, Jaroslav
    Vostry, Martin
    Kostecka, Arnost
    Bokorova, Radka
    Neuwirtova, Radana
    Siskova, Magda
    Caniga, Miroslav
    Sponerova, Dana
    Cermak, Jaroslav
    Mikulenkova, Dana
    Brezinova, Jana
    Michalova, Kyra
    Fuchs, Ota
    BLOOD, 2013, 122 (21)
12345